title: β1-noradrenergic system of the central amygdala is involved in state-dependent memory induced by a cannabinoid agonist, WIN55,212-2, in rat.
abstract: In the present study, we investigated effects of intra-central amygdala (intra-CeA) administrations of a β1-receptor agonist and antagonist, isoprenaline (isoproterenol) and atenolol respectively, on state-dependent memory induced by a cannabioid agonist, WIN55,212-2. This study used a step-through inhibitory avoidance task to assess memory in male Wistar rats. The results showed that post-training intra-CeA administrations of different doses of WIN55,212-2 (0.01, 0.05, 0.1 and 0.25μg/rat) decreased memory as revealed by a decrease in memory retrieval on the test day. The decrease in retrieval induced by post-training WIN55,212-2 (0.25μg/rat) was reversed by pre-test administration of the same dose of the drug, which was suggestive of drug-induced state-dependent memory. Although pre-test intra-CeA administrations of isoprenaline (0.01, 0.025 and 0.05μg/rat) alone had no effect, its co-administrations at doses of 0.025 and 0.05μg/rat with an ineffective dose of WIN55,212-2 (0.1μg/rat) restored memory retrieval that impaired by post-training WIN55,212-2 (0.25μg/rat). The results also showed that pre-test intra-CeA administrations of atenolol (0.01, 0.05 and 0.1μg/rat) alone had no effect, but at dose of 0.1μg/rat disrupted state-dependent memory induced by WIN55,212-2. Moreover, the improving effect of isoprenaline (0.025μg/rat) on retrieval of state-dependent memory induced by WIN55,212-2 (0.1μg/rat) was prevented by intra-CeA co-injections of atenolol. Taken together, our results suggest that the CeA may be potentially critical for state-dependent memory induced by WIN55,212-2 and the β1-noradrenergic receptor mechanism(s) interact with the cannabinergic system in the modulation of this kind of memory in the CeA.
authors.affiliation: Institute for Cognitive Science Studies, Tehran, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Ghiasvand
authors.forename: Ameneh
authors.initials: A
authors.lastname: Rezayof
authors.forename: Shamseddin
authors.initials: S
authors.lastname: Ahmadi
authors.forename: Mohammad-Reza
authors.initials: MR
authors.lastname: Zarrindast
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000679:Amygdala / Q000187:drug effects*; D000704:Analysis of Variance; D000818:Animals; D001262:Atenolol / Q000494:pharmacology; D001362:Avoidance Learning / Q000187:drug effects; D048588:Benzoxazines / Q000494:pharmacology*; D063386:Cannabinoid Receptor Agonists; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008568:Memory / Q000187:drug effects*; D009025:Morpholines / Q000494:pharmacology*; D009281:Naphthalenes / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018342:Receptors, Adrenergic, beta-1 / Q000378:metabolism*
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D000318:Adrenergic beta-Agonists; D048588:Benzoxazines; D063386:Cannabinoid Receptor Agonists; D009025:Morpholines; D009281:Naphthalenes; D018342:Receptors, Adrenergic, beta-1; D001262:Atenolol; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D007545:Isoproterenol